Although clinical trials have shown that Mounjaro can offer similar benefits, the treatment is not currently licensed for this purpose in the UK
Your cart Order note Order special instructions Discount Discount invalid
To assess the associations of semaglutide with incident CUD (first time diagnosis of CUD), the study population included 83,189 patients who had active medical encounters for the diagnosis of obesity in 6/202112/2022, were for the first time (new users design) prescribed semaglutide or non-GLP-1RA anti-obesity medications (bupropion, naltrexone, orlistat, topiramate, phentermine) [39] during 6/2021-12/2022 (time zero or index event), had no diagnosis of CUD on or before the index event and had a diagnosis of at least one of obesity-associated comorbidities (T2D, hypertension, hypercholesterolemia, hyperlipidemia, heart diseases, stroke) on or before the index event
Real user feedback and lab reports tell a different story than the flashy ads you see on social media
The SELECT trial, which evaluated semaglutide 2.4 mg against placebo for cardiovascular outcomes in patients with overweight and obesity without type 2 diabetes, showed significant decreases in total cholesterol, LDL-C, and triglycerides and an increase in HDL-C at 39.8 months [48]
It is possible
